ERNA

Healthcare Biotechnology

Ernexa Therapeutics Inc.

$2.24

-0.46 -17.04% today

Price History

Not enough data

Key Stats

Market Cap

3.66M

Avg Volume

455,755

EPS

-$11.00

52W High

$71.50

52W Low

$2.20

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-0.23

P/B Ratio

0.82

EV/EBITDA

0.02

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(320.7%)

Return on Assets

(105.6%)

Liquidity & Leverage

Current Ratio

2.01

Quick Ratio

1.74

Debt / Equity

0.11

Total Cash

5.03M

Total Debt

349,000

About

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.